Christine I Chen
Overview
Explore the profile of Christine I Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chan H, Chen C, Reece D
Curr Hematol Malig Rep
. 2017 Mar;
12(2):96-108.
PMID: 28317082
Purpose Of Review: New risk stratification systems and treatment strategies have been introduced in recent years. We aim to provide an overview of these recent changes and summarise these data...
12.
Chen C, Paul H, Wang T, Le L, Dave N, Kukreti V, et al.
Br J Haematol
. 2014 Mar;
165(5):731-3.
PMID: 24611934
No abstract available.
13.
Chen C, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda V, et al.
Br J Haematol
. 2013 Jun;
162(4):483-8.
PMID: 23772701
Involvement of the central nervous system (CNS) in multiple myeloma (MM) is a rare complication, with reported survival of <6 months. This report describes 37 MM patients with leptomeningeal and/or...
14.
Gerrie A, Mikhael J, Cheng L, Jiang H, Kukreti V, Panzarella T, et al.
Br J Haematol
. 2013 Apr;
161(6):802-10.
PMID: 23594335
Dexamethasone ± thalidomide with infusion of cisplatin, doxorubicin, cyclophosphamide, and etoposide [D(T)PACE] is generally reserved as salvage therapy for aggressive multiple myeloma (MM) or plasma cell leukaemia (PCL) resistant to...
15.
Chen C
Curr Hematol Malig Rep
. 2012 Dec;
8(1):7-13.
PMID: 23254517
Lenalidomide is a member of the immunomodulatory agents (IMiDs), and is currently approved for use in myelodysplastic syndromes and multiple myeloma. In chronic lymphocytic leukemia (CLL), lenalidomide has anti-tumor activity...
16.
Chen C, Bergsagel P, Paul H, Xu W, Lau A, Dave N, et al.
J Clin Oncol
. 2010 Dec;
29(9):1175-81.
PMID: 21189385
Purpose: Lenalidomide is an oral immunomodulatory drug with multiple effects on the immune system and tumor cell microenvironment leading to inhibition of malignant cell growth. Based on encouraging reports of...
17.
Chen C, Kouroukis C, White D, Voralia M, Stadtmauer E, Stewart A, et al.
J Clin Oncol
. 2007 Mar;
25(12):1570-5.
PMID: 17353550
Purpose: To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's macroglobulinemia (WM). Patients And Methods: Symptomatic WM patients, untreated or previously treated, received bortezomib 1.3 mg/m2 intravenously days...
18.
Trieu Y, Trudel S, Pond G, Mikhael J, Jaksic W, Reece D, et al.
Mayo Clin Proc
. 2005 Dec;
80(12):1578-82.
PMID: 16342650
Objective: To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem...
19.
Stewart A, Chen C, Howson-Jan K, White D, Roy J, Kovacs M, et al.
Clin Cancer Res
. 2004 Dec;
10(24):8170-6.
PMID: 15623591
We report a multicenter, randomized phase II trial conducted to assess the tolerability of combined thalidomide and prednisone maintenance in multiple myeloma. Eligibility required administration of melphalan (200 mg/m2) with...
20.
Chang H, Sloan S, Li D, Zhuang L, Yi Q, Chen C, et al.
Br J Haematol
. 2004 Mar;
125(1):64-8.
PMID: 15015970
The frequency and prognostic relevance of translocations t(11;14) and t(4;14), the most common translocations involving the immunoglobulin heavy chain (IgH) gene in multiple myeloma (MM), were investigated in 128 patients...